Biegel & Waller’s Axsome Therapeutics AXSM Stock Holding History

Biegel & Waller’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-8,792	Closed	-$226K	–	75
2019 Q2	$226K	Buy	+8,792	New	+$176K	0.12%	69

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Biegel & Waller's AXSM Position: Q3 2019 in Review

Biegel & Waller sold out of Axsome Therapeutics (AXSM) in Q3 2019, closing a stake of 8,792 shares — an estimated $226K sold.

Biegel & Waller first reported a position in AXSM in Q2 2019 and held it in 1 quarter. The position peaked at $226K in Q2 2019. 111 funds tracked by Wall St. Rank hold AXSM as of Q3 2019.

Biegel & Waller reported no remaining Axsome Therapeutics position as of Q3 2019 after selling out during the quarter.
Biegel & Waller sold 8,792 Axsome Therapeutics shares in Q3 2019, an estimated $226K.
Biegel & Waller first reported a position in Axsome Therapeutics in Q2 2019 and held it in 1 quarter.
Biegel & Waller's Axsome Therapeutics position peaked at $226K in Q2 2019.
111 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2019.

Based on Biegel & Waller's 13F filing for Q3 2019, filed 15 Oct 2019.